Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat in Relapsed or Refractory Cutaneous T-Cell Lymphoma
NCT07854639Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zeprumetostat in cutaneous T-cell lymphoma (CTCL), sponsored by Peking University First Hospital. Primary endpoint: Objective Response Rate maintained for at least 4 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07854639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854639.